Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azathioprine and 6-mercaptopurine are thiopurine immunomodulators used primarily for the maintenance of remission in inflammatory bowel diseases, including Crohn's disease. Azathioprine acts as a prodrug that is non-enzymatically cleaved to 6-mercaptopurine, which is then further metabolized into active thioguanine nucleotides. These metabolites incorporate into DNA and inhibit de novo purine synthesis, leading to the suppression of T- and B-lymphocyte proliferation and a reduction in immune-mediated inflammation. In clinical practice and trials like the PIBD-Net study (NCT02852694), they are often used interchangeably or as a treatment arm to maintain steroid-free remission in pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azathioprine + 6-mercaptopurine.